Abstract The skeleton originates from stem cells residing in the sclerotome and neural crest that undergo proliferation, migration, and commitment.
Introduction
Notch signaling is an important evolutionarily conserved pathway, and understanding of its pleiotropic functions involved in cell fate determination, proliferation, apoptosis, and differentiation has been a continuous effort since its original description in the Notch Drosophila mutant by Morgan in 1917 [1] . Notch signaling contributes to tissue maintenance and/or renewal in the adult skin, hematopoietic system, and central nervous system and is implicated in various cancers. The Notch receptors and their ligands are transmembrane proteins that require cell-to-cell physical interaction between neighboring cells. Mammals have four Notch receptors (NOTCH 1-4) and 12 ligands grouped into four classes based on the structural motifs: (1) DSL (Delta/Serrate/LAG-2)/DOS (Delta and OSM-11-like proteins)-containing ligands DLL1 (Delta-like 1), JAG1, and JAG2 [2] ; (2) DSL-only ligands DLL3 and DLL4; (3) DOS coligands DLK1 and DLK2; (4) noncanonical ligands DNER, MAGP1, MAGP2, F3/Contactin1, and NB-3/Contactin6 [3] . Notch receptors undergo two sequential proteolytic cleavages upon binding to their cognate ligands presented on neighboring cell surfaces [4] . The interaction between the ligand and Notch receptor results in a cleavage at the extracellular domain of the receptor by metalloproteinase tumor necrosis factor-a converting enzyme and is followed by cleavage of the transmembrane domain by a csecretase complex consisting of Presenilin 1 and Presenilin 2 [5, 6] . Consequently, the Notch intracellular domain (NICD) is released from the plasma membrane and translocates to the nucleus. In the nucleus, the NICD interacts with RBPJ and Mastermind-like (MAML), displacing the corepressor complex bound by RBPJ to transform RBPJ into a transcription activator [7] . This transcriptionally active complex induces the expression of basic helix-loophelix (bHLH) family genes such as Hairy Enhancer of Split (HES)-family genes-Hes1, -3, -5, and -7-and HES related with a YRPF motif-family genes-Hey1, Hey2, and HeyL. Both the HES and HEY families function as transcriptional repressors regulating progenitor cell fate in many tissues such as muscle, neuron, and hematopoietic cells [8, 9] . Less well understood is the process termed ''noncanonical Notch signaling,'' or ''Rbpj-independent Notch signaling.'' Here, Rbpj deficiency does not recapitulate Notch deficiency as exemplified by Drosophila crystal cell differentiation [10] , mammalian skin [11] , or heart development [12] .
Here, we will focus on the physiological role of Notch signaling in bone and cartilage development and in maintaining skeletal homeostasis and its involvement in osteoarthritis (OA) and osteosarcoma. Finally, we will discuss the bone as a hematopoietic stem cell (HSC) niche whereby interaction with its microenvironment supports HSC homeostasis.
Notch Signaling and Human Skeletal Diseases
The role of Notch signaling during skeletogenesis was first identified in somitogenesis and patterning. Notch1 and Dll1 are highly expressed in the presomitic mesoderm of mouse embryos. Demonstratively, Notch1 null mouse embryos revealed significant delay and disorganization during somitogenesis [13] . Rbpj null embryos exhibited more severe defects in somitogenesis as a consequence of the complete loss of Notch signaling [14] . Presenilin1 null mice and Dll3 mutant mice (Pudgy mice) also have axial skeletal defects [15, 16] . Human mutations in Notch signaling genes give rise to spondylocostal dysostosis (SCDO), Alagille syndrome (AGS), and Adams-Oliver syndrome (AOS) [17] . SCDO patients exhibit characteristic vertebral segmentation defects caused by disruption of Notch signaling due to homozygous mutations in DLL3 (Notch ligand), MESP2 (downstream target), HES7 (downstream target), or LFNG (glycosylase). AGS, a multisystem disorder, results from loss of function of JAG1 or NOTCH2 and is a condition in which hemivertebrae and fractures are frequently seen and represent as diagnostic criteria [18] . Recently, heterozygous missense mutations in RBPJ were identified as causative mutations for autosomal dominant AOS, of which distal limb defect is a prominent and consistent finding [17] .
Apart from its role in embryonic axial skeleton patterning, recent studies have demonstrated that the Notch pathway also regulates developmental and homeostatic processes of cartilage and bone. Hajdu-Cheney syndrome, an autosomal dominant disease, is characterized by craniofacial anomalies, acro-osteolysis, Wormian bones, and osteoporosis [19] , caused by heterozygous mutations in NOTCH2. These mutations result in a truncated protein lacking the proteolytic degradation domain of the NOTCH2 receptor. This leads to sustained NOTCH2 activation [20, 21] . Also supporting Notch's role in bone homeostasis is a genomewide association study demonstrating an association between bone mineral density and JAG1 polymorphisms in a Chinese population and in a population of mixed European and Chinese ancestry [22] [23] [24] . Hence, Notch signaling is essential for proper skeletal patterning during development and for postnatal skeletal homeostasis.
Notch Signaling During Chondrocyte Differentiation and Osteoarthritis
The original shape and structure of the skeletal system are derived from cartilage tissue, which plays roles in the support and maintenance of the growth plate and articular cartilage [25] . Beginning with mesenchymal stem cell condensation, the chondrocyte is formed through an orderly differentiation process starting with resting cells to proliferating chondrocytes, transforming into prehypertrophic chondrocytes and then hypertrophic chondrocytes, and then finally terminally differentiating into hypertrophic chondrocytes [26] . Input from multiple signaling pathways, including transforming growth factor b (TGFb), fibroblast growth factor (FGF), Wnt, indian hedgehog (IHH), and Notch signaling pathways, is integrated into a ''morphogenetic rheostat'' [27] to provide temporal and spatial cues for proper differentiation [27] [28] [29] [30] . Human mutations disrupting functions of these pathways underlie the mechanism of various skeletal disorders. A review from our lab [30] has provided a detailed description of these signaling pathways in skeletal dysplasias; here, we will focus on the physiological and pathological functions of Notch signaling with implications for cancer therapy and regenerative medicine.
The in vivo function of Notch during the early steps of chondrogenesis was investigated by abolishing Notch signaling in limb bud mesenchymal stem cells by crossing Prx1-Cre with different conditional inactivation alleles of Notch signaling components. Presenilin 1/2 DKO (Presenilin1 flox/flox ; Presenilin 2 -/-; Prx1-Cre; PPS mice), Notch 1/2 DKO (Notch1 flox/flox ; Notch2 flox/flox ; Prx1-Cre; PPN mice) [31] , and Rbpj CKO (Rbpj flox/flox ; Prx1-Cre) [32] exhibit a consistent phenotype: a delayed chondrocyte hypertrophy at E14.5-E15.5 and an elongated hypertrophic cartilage zone perinatally, suggesting Notch signaling is required to initiate chondrocyte hypertrophy. To explain the elongated hypertrophic zone, two possibilities are considered: (1) accelerated hypertrophic chondrocyte differentiation and (2) delayed chondrocyte apoptosis to remove terminally differentiated chondrocytes [33] . The length of the hypertrophic zone is reduced at the onset of hypertrophy (E14.5-E15.5) in all mutant mice identified above, negating the first explanation. Therefore, it is probable that a delay in terminal differentiation and programed cell death occurred as a consequence of Notch loss of function in chondrocyte progenitor cells. Similarly, the consequences of Notch signaling deficiency in chondrocyte progenitors were examined using a different Cre line: Sox9 knock-in Cre, where endogenous Sox9 promoter drives Cre expression in the osteochondroprogenitors [34] . Inactivation of Rbpj with knock-in Sox9-Cre led to dwarfism, impaired matrix degradation, and inhibited vasculature invasion. Molecularly, Mmp13 and Vegf expression were reduced, explaining the matrix and vasculature defects [41] . This corroborates with data from previous mutant mice using Prx1-Cre suggesting that Notch signaling is required for the initiation of chondrocyte maturation, i.e., hypertrophy and terminal differentiation.
A limitation of using Prx1-Cre and Sox9 knock-in Cre mouse lines is that Cre is expressed in limb bud mesenchymal condensations, which contributes to osteoblastic and chondrogenic lineages. To further dissect the tissuespecific requirement of Notch in osteochondroprogenitors and chondrocytes, Col2a1-Cre and Col2a1-Cre ERT mouse lines were employed, respectively. Deletion of Rbpj using Col2a1-Cre gives rise to a longer hypertrophic zone [35] . However, Col2-Cre; Rbpj flox/flox mice display a milder degree of elongation than that of Prx1-Cre; Rbpj flox/flox . Col2-Cre; Rbpj flox/flox mice display a shorter hypertrophic zone marked by Col10a1 expression at E14.5 [32] . The reduction in the length of Mmp13 expression in chondrocytes strongly suggests a delay in chondrocyte terminal differentiation, thereby reducing chondrocyte apoptosis and removal, which may account for the accumulation of hypertrophic chondrocytes at E18.5 and later time points.
To consider the pathological gain of Notch function in mesenchymal stem cells or osteochondroprogenitors, Prx1-Cre; Rosa Notch1ICD and Col2a1-Cre; Rosa Notch1ICD mutants were examined, respectively. The two mutant mice shared similar phenotypes such as inhibition of cartilage formation [32, 35, 36] and suppression of Sox9, Col2a1, and Aggrecan (Acan) expression, suggesting an inhibitory effect of Notch signaling on chondrocyte differentiation. Chondrocyte proliferation was inhibited in Col2a1-Cre; RosaNotch1ICD mice, while mesenchymal stem cell proliferation was increased in Prx1-Cre; Rosa Notch1ICD mice [35, 36] . Taken together, Notch gain of function (GOF) in chondrocytes inhibits chondrocyte differentiation and may have a differential effect on chondrocyte proliferation in a context-dependent manner.
To assess the Notch GOF effects on hypertrophic chondrocytes, an in vitro assay was performed since Notch GOF mice have few mature chondrocytes in the limb. Enriched epiphyseal chondrocytes from Rosa Notch1ICD mice were infected with adenovirus encoding Cre recombinase to induce NICD expression [37] . This leads to upregulation of hypertrophic markers such as Col10a1 and Mmp13 and a notable downregulation of Nfatc1 (nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 1), a key regulator of osteoclasts [38] and a target of Notch signaling in osteoblasts [39] . A rescue experiment showed that expression of the constitutive form of Nfatc1 reversed the increased Col10a1 and Mmp13 in the Notch GOF chondrocytes, suggesting that overactivated Notch signaling misregulates hypertrophic markers through suppressing Nfatc1 [37] .
To understand the molecular mechanisms of Notch signaling during chondrocyte differentiation it is necessary to distinguish between the function of Rbpj-dependent (canonical) and Rbpj-independent (noncanonical) Notch signaling. Rbpj deletion in the context of Notch activation provides an insight into which aspects of the Notch GOF phenotype are Rbpj-dependent. Dong et al. [36] found that deletion of Rbpj in Prx1-Cre; Rosa Notch1ICD mice rescued the chondrodysplasia phenotype in the limbs. The restored cartilage in these mice was indistinguishable from the cartilage of Prx1-Cre; Rbpj flox/flox mice, supporting the concept that Rbpj is the sole mediator of Notch signaling function during limb cartilage development. Kohn et al. [32] removed Rbpj in Col2a1-Cre ERT2 ; Rosa Notch1ICD mice, which did not reverse the inhibited chondrocyte proliferation in the limbs but rather reversed the accelerated chondrocyte hypertrophy and terminal differentiation due to Notch activation. Since cartilage development in the limbs is dependent upon canonical Notch signaling, a related question is whether this process depends on Rbpj during vertebral cartilage development. Our recent study showed the nearly complete loss of cartilage in the vertebral column of Col2a1-Cre; Rosa Notch1ICD mice [40] . Upon removal of Rbpj in the GOF background, cartilage formation was only partially restored, exhibiting a cleft between two hemivertebrae with nearly complete loss of ossification in the center of the vertebrae. This is in contrast to the vertebral column of Col2a1-Cre; Rbpj flox/flox mice, which show no difference from control mice, suggesting that other factors than Rbpj may be recruited to mediate Notch GOF in the vertebrae. In terms of how Rbpjdependent Notch signaling regulated chondrogenesis in the vertebrae, Sox9 expression was reduced in the Notch GOF vertebrae but was qualitatively restored in GOF Rbpj flox/flox mice. It was also shown that Rbpj can associate with the Rbpj consensus binding motifs within the Sox9 promoter, leading to a direct regulation of Sox9 in trans. In summary, while Rbpj-dependent Sox9 suppression partially explains the chondrogenic phenotypes in GOF mice, an Rbpj-independent Notch mechanism is postulated to govern chondrocyte differentiation and endochondral ossification.
Given the pivotal role of Notch in chondrocyte hypertrophy, an intriguing question is whether Notch signaling is associated with OA. OA, a degenerative disease of cartilage, presents with loss of articular cartilage markers, articular chondrocyte hypertrophy and subchondral bone remodeling. Loss of Notch signaling in adult cartilage, accomplished by Rbpj deletion with Col2a1-Cre ERT , a tamoxifen-inducible Cre line, ameliorates the progression of OA in a destabilization surgery model [41] . In relation to human articular cartilage, the distribution of stem cell markers such as NOTCH1, STRO1, and vascular cell adhesion molecule 1 (VCAM1) was examined. NOTCH1 is expressed in 78 % of the superficial zone of the articular cartilage cells, which is significantly higher than in the middle or deep zone. In the fibrillated OA cartilage, the NOTCH1-positive cell population was significantly increased (up to 84 %) in the superficial zone [42] . Similarly, another human study comparing the expression profiles of Notch signaling genes between OA cartilage and normal articular cartilage suggests that Notch pathway genes are expressed at a higher level in the OA cartilage, which is consistent with the acceleration of chondrocyte hypertrophy observed in OA models [43] [44] [45] . This is supportive of the beneficial effect of reducing Notch signaling in the mouse model. It will be interesting to explore how the development of antibodies against Notch receptors and their ligands may influence OA treatment.
Notch Regulates Osteoblast Commitment, Proliferation, and Differentiation
Osteoblasts are bone-forming cells differentiated from mesenchymal precursors in the bone microenvironment. The role of Notch signaling in osteoblast differentiation has been examined by several in vitro studies and in vivo mouse models. In vitro studies suggested a potential role for Notch signaling in the regulation of osteoblast differentiation but with conflicting results. Tezuka et al. [46] detected the expression of Notch1 in MC3T3-E1 osteoblastic cells at the early stages of differentiation. When NICD was delivered by adenoviral vectors to MC3T3-E1 cells, a significant increase in calcified nodule formation was observed. Furthermore, Notch activation stimulated the multipotent mesenchymal cell line C3H10T1/2 to favor osteoblast differentiation rather than adipogenic differentiation. Similarly, primary human bone marrow mesenchymal stem cells also induced both spontaneous and stimulated osteoblastic cell differentiation by Notch activation. Consistently, the Notch target gene Hes1 was shown to interact with Runx2 and increase the Runx2 transactivation effect on enhancers of osteoblast-specific genes [47] . In addition, Maml (transcription activator of Notch signaling) was shown to enhance transactivation of Runx2 in bone development. Overall, these observations suggest that osteoblast differentiation is stimulated by Notch signaling. On the other hand, others have shown a suppressive role of Notch signaling in osteoblast differentiation by inhibiting Wnt/b-catenin signaling after overexpressing Notch1 in ST-2 and MC3T3-E1 cells [48, 49] .
The function of Notch in the osteoblast lineage and its differentiation were well defined by in vivo cell typespecific Notch gain-and loss-of-function mouse models. Transgenic mice expressing Notch1ICD under the control of the 2.3-kb collagen type 1 (Col1a1) promoter drive expression of the activated Notch receptor specifically in committed osteoblasts [50] . The transgenic mice showed a dramatic increase in osteoblast proliferation resulting in a severe osteosclerotic phenotype. However, the sclerotic bones were formed by disorganized woven bone, suggesting a defect in osteoblast maturation. This was confirmed by decreased expression of osteocalcin (Ocn), a mature osteoblast marker from the calvarial tissue of mutant mice. Interestingly, Osterix was upregulated along with Cyclin D and Cyclin E in this transgenic mouse, accounting for the dramatic expansion of the immature osteoblast population in these mutant mice. Mechanistically, Notch1ICD physically interacts with Runx2 and inhibits its transactivation on Ocn, demonstrating that Notch signaling suppresses Runx2 to maintain an immature osteoblast pool at the expense of mature osteoblast differentiation.
In contrast to these findings, expression of Notch1ICD under the control of the 3.6-kb Col1a1 promoter showed osteopenia due to inhibition of osteoblast progenitor differentiation [51] . This uncovers contrasting roles for Notch in two different cell populations. When Notch1ICD expression was restricted to committed osteoblasts in 2.3-kb Col1a1 transgenic mice, terminal differentiation of osteoblasts was inhibited, allowing for expansion of immature progenitor cells, leading to increased formation of woven bone. However, when Notch1ICD expression was initiated in progenitor cells under the control of the 3.6-kb Col1a1 promoter, the early differentiation was compromised and led to a decreased number of mature osteoblasts and an osteopenic phenotype.
The loss of function of Notch signaling in committed osteoblasts was studied by deletion of Presenilin1 and Presenilin2 using 2.3-kb Col1a1-Cre mice where the activation of all four Notch receptors was abolished in committed osteoblasts [50] . This double-knockout mouse did not show any immediate postnatal bone phenotype. However, the mice did show age-related osteoporosis due to increased osteoclastogenesis caused by a decreased Opg level. To evaluate the function of Notch during early skeletal formation, Presenilin1 and Presenilin2 were deleted using Prx1-Cre (PPS mice) in which Notch function was abolished in osteoblast progenitors [31] . Unlike Col1a1 2.3-kb-Cre mediated deletion of Presenilins, PPS mice exhibit a high bone mass phenotype at 2 months of age. Deletion of Notch1 and Notch2 via Prx1-Cre (PNN mice) mimicked the high-bone mass phenotype of PPS mice. Interestingly, PPS and PNN mice progressed to a state of significant bone loss as they aged due to reduced osteoblast numbers and increased bone resorption. The bone marrow mesenchymal progenitors from PNN mice produced fewer CFU-f (colony forming units-fibroblast) and CFU-ob (colony forming units-osteoblast) and fewer differentiated adipocytes. The deletion of Rbpj in mesenchymal progenitors recapitulated the high-bone mass phenotype in PPS and PNN mice [39] . The progenitorspecific Rbpj deficiency resulted in an increased osteoblast number, a diminished progenitor pool, and rapid age-related bone loss.
The phenocopy of Rbpj flox/flox ; Prx1-cre with PNN or PPS mice suggests canonical Notch signaling is dominant in regulating osteoblasts and osteoblast-osteoclast coupling. Furthermore, functions of canonical Notch targets such as Hes1, Hey1, and HeyL were examined in genetic mouse models or in vitro cell studies. Global Hey1 deletion leads to decreased BV/TV in adult mice; interestingly, ubiquitous expression of Hey1 also leads to osteopenia. In both situations osteoblast differentiation and mineralization are inhibited and osteoclastogenesis is accelerated [52] . Osteoblast-specific GOF of Hes1 causes osteopenia by suppressing osteoblast differentiation. Loss of Hes1 in the Hes3 and -5 global null background manifests a bone mass increase from 1 month up to 3 months, which is different from Rbpj-deficient mice whose bone mass showed a significant decline by 4 months [53] . Moreover, both HeyL -/-and HeyL -/-, Hey1 ?/-exhibit high bone mass at 2 months due to increased mature osteoblast numbers [39] . These studies support that canonical Notch signaling is a central regulator of osteoblast differentiation at early stages. A ChIP-seq (chromatin immunoprecipitation followed by high-throughput sequencing) study demonstrated that Nfatc1 is a critical mediator of Notch function in osteoblasts. The recruitment of Hey1 to the promoter of Nfatc1 leads to transcription suppression of Nfatc1, and deletion of Rbpj relieved this repression in bone. Moreover, a pharmacological inhibitor of Nfatc1 alleviated the abnormal high-bone mass phenotype caused by deletion of Rbpj. Overall, Notch-Rbpj signaling functions in part via Hey1-mediated suppression of Nfatc1 to suppress osteoblastogenesis [39] . Considering another Nfat family member, Nfatc2, in vitro cell studies demonstrated that Notch1, Hey1, and Hey2 inhibit Nfatc2 transactivation by suppressing Gsk3b, which activates Nfatc2 by phosphorylation, in ST-2 stromal cells as well as in primary osteoblast cells from Notch GOF mice [37] .
The consequence of activation of Notch signaling in osteocytes, terminally differentiated osteoblasts, was recently examined using dentin matrix protein 1 (Dmp1) promoter-Cre [54] . Osteocytes are embedded in the mineralized matrix of the bone in distinct lacunae [55, 56] . Osteocytes are dendritic cells that communicate through a canalicular network with each other and with osteoblasts and osteoclasts [57] . Osteocytes play a crucial role in mechanotransduction. When osteocytes were ablated, mice exhibited severe bone loss and microstructural deterioration [58] . Dmp1-Cre; Rosa Notch1ICD mice exhibited increased bone volume due to initial inhibition of bone resorption at 1 month. This phenotype persisted at 3 months of age due to an increased osteoblast number, suggesting that Notch signaling also contributes to the non-cell-autonomous function of osteocytes in the regulation of osteoclasts and osteoblasts. Concordant with this, induction of Notch1 expression in MLOY4 cells (an osteocytic cell line) in response to a fluid flow shear stress demonstrated that Notch may regulate mechanotransduction in osteocytes [54] .
Together, these studies show that during the early stages of osteogenesis Notch maintains mesenchymal progenitor cells and differentiation potency. Upon loss of Notch signaling, the program of osteoblastic commitment is initiated in conjunction with loss of mesenchymal stem cell multipotency. Once committed, Notch signaling is required for osteoblast turnover and osteoclast regulation during bone remodeling to maintain a sufficient pool of osteoblasts and an appropriate pace of bone remodeling. In our and other study of Notch GOF in committed osteoblasts causes abnormal proliferation of immature osteoblasts, contributing to a high-bone mass phenotype. Canonical Notch signaling is responsible for mediating the Notch functions during different stages of osteoblast differentiation as well as in the pathogenic GOF conditions [39, 59] .
Notch Regulates Osteoclastogenesis
Osteoclastogenesis is modulated by the ratio of receptor activator of nuclear factor jB ligand (RANKL), which induces osteoclast formation, and osteoprotegerin (OPG), a soluble protein that binds and inhibits RANKL [60] . In an in vitro study using immobilized Notch ligand Delta-1, it was suggested that osteoclastogenesis is inhibited when Notch is activated in the osteoclast lineage [61] . Additionally, deletion of Notch1, Notch2, and Notch3 in murine myeloid cells was seen to enhance osteoclast precursor proliferation and differentiation compared to wild type in response to macrophage colony-stimulating factor, confirming the cell-autonomous function of Notch signaling in osteoclast differentiation [62] .
In vivo RANKL expression was upregulated in PNN mice, and Opg levels were decreased [31] . Similarly, deletion of presenilins 1/2 in the committed osteoblast by Col1a1 2.3kb-Cre resulted in a decreased level of Opg and increased osteoclastogenesis, thereby causing osteopenia [50] . These observations further indicate that Notch signaling regulates osteoclastogenesis in a non-cell-autonomous manner through Opg expression by osteoblasts in vivo. Recent studies of osteocytes showed that these terminally differentiated cells from osteoblasts are actively involved in bone remodeling and bone resorption through expression of RANKL. The suppression of bone resorption in Dmp1-Cre; Rosa Notch1ICD mice is explained by an increased level of Opg, consistent with previous studies [54] .
In contrary, Notch signaling was shown to activate osteoclastogenesis in different contexts. Fukushima et al. [63] demonstrated that Jagged1 could increase osteoclast differentiation in vitro by specifically activating Notch2 ICD, which augmented RANKL-induced NFjB signaling. Moreover, in a pathological context, tumor-expressed JAG1 acts as a potent mediator in promoting the vicious cycle of breast cancer metastasis to the bone by activating preosteoclast differentiation [64] . Consequently, c-secretase inhibitor treatment reversed this prometastatic function of JAG1 by disrupting the Notch pathway. In a K/BxN serum-induced arthritic mouse model [65] , the differential regulation of osteoclastogenesis by Notch2/ Dll1 and Notch1/Jag1 axes was demonstrated. Blockade of Dll1 by anti-Dll1 monoclonal antibody ameliorated arthritis in this mouse model [66] . Collectively, these studies highlight that cell-autonomous Notch signaling plays a key role in osteoclast differentiation and is regulated through differential ligand-receptor interactions. The multiplicity of cell types and the ligand-receptor specificity employed by Notch signaling draw attention to these contextual issues. Future identification and delineation of the mechanism underlying this complexity will help tease out the dominant ligand or cell type that takes part in a particular pathological context of bone-related diseases.
Osteoblasts Regulate HSC via Notch Signaling
In bone marrow, osteoblasts are active participants in regulating hematopoiesis by providing regulatory signals for hematopoietic cells. Homeostasis of the hematopoietic system is maintained by the capacity of HSCs to undergo differentiation, forming mature blood cell types and selfrenewal to replenish the HSC pool throughout life. Because of the juxtaposition of the endosteum and HSCs, osteoblasts lining the endosteum are postulated to form the specific microenvironment (so-called niche) to support HSC functions. The first functional study of osteoblast regulation of hematopoiesis in vivo was done by targeted expression of thymidine kinase in osteoblasts where gancyclovir administration induced cell death. The ablation of osteoblasts is correlated with a dramatic decrease in bone marrow cellularity and extramedullary hematopoiesis [67, 68] . Withdrawal of gancyclovir resulted in a rapid recovery of hematopoiesis with increased bone formation.
Transgenic mice with expression of constitutively active parathyroid hormone/parathyroid hormone-related peptide receptor (PPR) under the control of the Col1a1 2.3-kb promoter demonstrated increased osteoblast numbers, increased expression of Jag1, and a concomitant increase in the HSC population [69] . Moreover, contact between the HSCs and Jag1-expressing osteoblasts was required for the HSC expansion, and the addition of a c-secretase inhibitor to stromal cells abrogated the HSC expansion in vitro. These data demonstrated that the osteoblast is one of the regulatory components of HSCs and employs Notch signaling for such an action. In contrast, deletion of either Jag1 or Notch1 in the bone marrow cells with Mx1-Cre did not lead to HSC defects under basal conditions [70] . When canonical Notch signaling was inhibited in adult HSCs by either expressing a dominant-negative MAML1 fused to GFP (DNMML) or by conditionally deleting Rbpj, these HSCs failed to show any phenotype in a competitive repopulation assay [71] . Although not absolutely required, Notch2 enhances the rate of generation of long-and shortterm repopulating HSCs and delays myeloid differentiation following bone marrow injury [72] . All together, these data suggest that Notch signaling may be dispensable for HSC development in the context of normal development but may be partially required for HSC repopulation after bone marrow injury.
Dysregulation of Notch Signaling and Osteosarcoma
Primary bone cancer consists of neoplastic cells in bone. The most common types of primary bone tumor are osteosarcoma (35 %), chondrosarcoma (30 %), and Ewing's sarcoma (16 %) [73] . As often seen in cancer, developmental pathways are recapitulated in crucial steps of cancer transformation, proliferation, and metastasis. The association of Notch signaling to the key steps of cancer progression has been illustrated by both human and animal studies. Expression of Notch pathway genes has been analyzed in osteosarcoma specimens, in which NOTCH2, JAG1, HEY1, and HEY2 are upregulated while NOTCH1 and DLL1 are downregulated, compared to those of normal human bone [74] . Similarly, we demonstrated NOTCH1, JAG1, HES1, and HEY1 expressions are significantly higher in human osteosarcoma compared to human osteoblasts [75] . Transcription profiling of osteosarcoma tumors from p53 heterozygous mice, which develop osteosarcoma at a high frequency (24 %), confirms the human findings, showing elevated Jag2, Hes1, Hey1, and Dll4 expressions [75] [76] [77] . A c-secretase inhibitor, a potent agent to inhibit Notch signaling transduction, suppressed human osteosarcoma cell line (SaOS2, HOS, and 143B) proliferation. Importantly, xenograft of SaOS2 or 143B in nude mice showed that either a c-secretase inhibitor or overexpression of DNMML to abolish Notch transcriptional regulation can reduce primary tumor burden by 20-80 % [74, 75] . The molecular mechanism is attributed to a downregulation of Cyclin D, Cyclin E1, Cyclin E2, SKP2, and c-Myc expressions when Notch signaling is inhibited [74] .
Approximately 30 % of patients with localized osteosarcoma and 80 % of patients presenting metastatic disease experience relapse [73] . Analysis of Notch pathway gene expressions identified higher levels of Notch1, Notch2, Dll1, and Hes1 expression in metastatic osteosarcoma cell lines, compared to normal osteoblast or nonmetastatic osteosarcoma [78] . A retrospective study on HES1 expression in human osteosarcoma specimens showed an inverse relationship between HES1 level and patients' survival. The notion that Notch promotes metastasis is supported by the ability of the c-secretase inhibitor or DNMML to decrease invasiveness of osteosarcoma cell lines (OS187 and LM7) in a Matrigel transwell assay [79] . Notably, overexpression of DNMML suppressed the metastatic potency of OS187 using an intratibial injection xenograft model, albeit not changing the primary tumor growth or primary osteolytic lesion formation [79] . Epigenetic regulation of Notch is also seen in osteosarcoma progression and invasion; that role of miRNAs is relevant in these processes. Our recent study has demonstrated that miRNA-34c can directly regulate multiple components of the Notch pathway (Notch1, Notch2, and Jag1) during osteoblast differentiation in an in vivo mouse model [80] . Also, others showed the inverse correlation with an invasiveness of osteosarcoma tumors and expression of NOTCH1, NOTCH2, and DLL1 by the miRNA-34 family [81] . The association of Deltex1 with activated Notch receptor restrains the invasiveness of osteosarcoma cell OS187 as Deltex1 overexpression leads to Notch degradation and reduced invasiveness [82] .
In summary, pharmacological administration or genetic manipulation support that Notch signaling participates in the proliferation, invasion, and metastasis of osteosarcoma progression.
Future Directions
Advances in understanding the role of Notch in various cells of the skeleton have provided important insights into the etiology of skeletal conditions like osteosclerosis, osteoporosis, chondrodysplasia, OA, and osteosarcoma. Attempts to modulate Notch signaling pathways have been made to treat diseases such as osteosarcoma, graft-versushost disease and hematologic cancer in various mouse models. To translate these results into therapeutic reality, toxicity needs to be considered in terms of usage of csecretase inhibitors or pan-Notch receptor antibodies, which have demonstrated high intestinal toxicity in rodents [83, 84] . Antibodies that recognize the Notch negative regulatory region and antagonize individual Notch receptors may reduce or limit this adverse effect [83] [84] [85] . Ligand-specific antibodies against Dll1 and Dll4 further reduce the toxicity in treating a mouse model of graftversus-host disease [85] , suggesting a rational design of ligand neutralizing antibodies specific for targeted tissues, which may shed promising light on its application. The skeletal defects exhibited by Dll3 and Jag2 null mice and human skeletal diseases such as SCDO and AGS caused by mutations in DLL3 and JAG1 underscore the specific utilization of the Notch ligands in the context of skeletogenesis. Hence, defining functions and the molecular mechanisms of Notch ligands will allow us to delineate the signal-sending partners of the Notch pathway and to develop ligand-targeted therapy for skeletal disorders. Distinguishing canonical vs. non-canonical Notch signaling is the second concern. Increasing evidence suggests that Rbpj-independent Notch signaling governs differential responses to Notch stimulation (at least under pathological conditions). Identification of the noncanonical components and downstream targets with screening tools like RNA-seq, ChIP-seq or mass spectrometry may serve as an informative guide to test biological functions of noncanonical Notch signaling genes in cell studies or animal models. This may also lead to lower toxicity or higher efficacy by targeting only a small subset of a cell population where noncanonical signaling is active as demonstrated in heart development [12] .
In conclusion, Notch signaling regulates multiple steps of osteoblast development including osteoblast commitment, proliferation and maturation as well as functional interaction with osteoclasts and HSCs in the bone microenvironment (Fig. 1) . The requirement of Notch in cartilage during developmental processes and homeostasis provides new insights into skeletal disorders like SCDO and AGS beyond its well-understood function in patterning (Fig. 2) . Misregulation of Notch signaling and its association with cancer may lead to therapeutic innovations where manipulation of Notch signaling either canonically or noncanonically may be of benefit in reducing cancer risk, progression, or metastasis. 
